Table 2 Response rates

From: Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group

Response evaluation

Measurable disease no. (%)

CA 125 assessable no. (%)

Total no. (%)

Overall response

8 (31)

10 (43)

18 (37)

Stable disease

8 (31)

5 (22)

13 (27)

Progression

10(38)

6 (26)

16 (33)

Not evaluable

2 (9)

2 (3)

Total

26 (100)

23 (100)

49 (100)